Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06054555 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
A Phase 3 study of Melanoma, sponsored by Amgen.
- Active
- Registry status
- Phase 3
- Development phase
- 633
- Enrollment target
- 20
- Study locations
NCT06054555 is a Phase 3 study of Melanoma that is active but no longer recruiting, run by Amgen. The registered enrollment target is 633 participants, below the 704-participant average among 266 other Melanoma trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 19 states.
The verdict
NCT06054555, a Phase 3 study of Melanoma, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 633 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG ABP 206
Study Locations (20)
Río Negro Province
- Centro De Investigaciones Medicas Mar Del Plata (CIMMDP) - Rheumatology - Mar Del Plata
- Clínica Viedma - Oncology - Viedma
California
- Cancer and Blood Specialty clinic - Long Beach
Indiana
- Fort Wayne Medical Oncology and Hematology - Office of Clinical Research - Fort Wayne
Louisiana
- Our Lady of the Lake Physicians Group-Medical Oncology-Woman's Pavilion - Baton Rouge
Missouri
- Oncology Hematology Associates - Springfield
New York
- Hematology-Oncology Associates of Central New York, P.C. (HOA) - East Syracuse - CCOP - East Syracuse
Ciudad Autónoma de Buenos Aire
- Centro de Investigaciones Médicas y Desarrollo LC - Buenos Aires
Santa Fe Province
- Instituto De Oncologia De Rosario - Rosario
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 633 participants |
| Start Date | 2023-11-02 |
| Est. Completion | 2028-01-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06054555
The ClinicalTrials.gov registry entry for NCT06054555 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 633 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 704-participant average among 266 other Melanoma trials with a reported enrollment target (10% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT06054555 reports 20 study locations spanning 19 distinct geographic areas - top geographies include Río Negro Province, California, Indiana.
Frequently Asked Questions
What is clinical trial NCT06054555 about?
NCT06054555 is a clinical study titled "A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma". The purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma.
What is the current status of trial NCT06054555?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 633 participants. The study started on 2023-11-02. Estimated completion is 2028-01-25.
What conditions does trial NCT06054555 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT06054555?
The interventions under investigation include: Nivolumab (DRUG), ABP 206 (DRUG).
Who is sponsoring clinical trial NCT06054555?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06054555 being conducted?
This trial has 20 study locations across California, Indiana, Louisiana, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
RECRUITING · Phase 3
-
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
RECRUITING · Phase 3
-
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
ACTIVE NOT RECRUITING · Phase 3
-
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
ACTIVE NOT RECRUITING · Phase 3
-
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
ACTIVE NOT RECRUITING · Phase 3
-
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.